Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Traxler

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1995
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activityE Buchdunger, H Mett, U Trinks, et al.
International Journal of Cancer|April 9, 1998
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivoN B Lydon, H Mett, M Mueller, et al.
Journal of Medicinal Chemistry|November 14, 1997
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidinesP Traxler, G Bold, J Frei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinomaC C Solorzano, C H Baker, R Tsan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1994
4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activityE Buchdunger, U Trinks, H Mett, et al.
The Journal of Biological Chemistry|December 25, 1990
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitorsJ F Geissler, P Traxler, U Regenass, et al.
Cancer Research|June 13, 2000
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinomaC J Bruns, C C Solorzano, M T Harbison, et al.
Atherosclerosis|October 1, 1992
Effect of a novel series of macrocyclic hypolipidemic agents on plasma lipid and lipoprotein levels of four non-primate speciesJ C Gibson, H V Kothari, T M Genthe, et al.
Journal of Medicinal Chemistry|July 6, 2000
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesisG Bold, K H Altmann, J Frei, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1995
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activityE Buchdunger, H Mett, U Trinks, et al.
International Journal of Cancer|April 9, 1998
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivoN B Lydon, H Mett, M Mueller, et al.
Journal of Medicinal Chemistry|November 14, 1997
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidinesP Traxler, G Bold, J Frei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinomaC C Solorzano, C H Baker, R Tsan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1994
4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activityE Buchdunger, U Trinks, H Mett, et al.
The Journal of Biological Chemistry|December 25, 1990
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitorsJ F Geissler, P Traxler, U Regenass, et al.
Cancer Research|June 13, 2000
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinomaC J Bruns, C C Solorzano, M T Harbison, et al.
Atherosclerosis|October 1, 1992
Effect of a novel series of macrocyclic hypolipidemic agents on plasma lipid and lipoprotein levels of four non-primate speciesJ C Gibson, H V Kothari, T M Genthe, et al.
Journal of Medicinal Chemistry|July 6, 2000
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesisG Bold, K H Altmann, J Frei, et al.
Pageof 3